Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma

摘要: Abstract Background Peripheral neuropathy is one of the most common dose-limiting toxicities associated with bortezomib; it can lead to dose reductions or therapy discontinuation. Obesity has been identified as being a risk factor for development peripheral other neurotoxic anticancer agents. We aimed evaluate impact obesity on incidence and severity bortezomib-induced neuropathy. Patients Methods This retrospective, single-center study patients treated subcutaneous bortezomib between January 1, 2012 June 2017. Eligible received at least 1 full cycle had previously untreated, newly diagnosed multiple myeloma. who intravenous concomitant thalidomide were excluded. divided into 3 groups based their body mass index (BMI): normal/underweight (BMI  Results A total 143 fitting inclusion criteria identified. across similar doses schedules (weekly vs. biweekly). Obese an increased in developing (56.4%) compared (17.3%) overweight (26.9%). Further analysis showed that, patients, was not found be grade 4 (P = .451). Conclusion higher non-obese patients.